Reader sentiment, not investment advice. One vote per visitor; click again to change it.
ROIV is priced at $36.38 right now, down 0.52% on the session. That puts its market value at $26.28B, 476th largest among the 800 stocks we cover.
Over the past 52 weeks it has traded between $15.25 and $42.50, so it sits 14.4% below the top of that range.
In the quarter ended Jun 2026 the company brought in $1.44M of revenue, down 33.5% from a year earlier, and a net loss of $290.61M.
10 analysts follow the stock and the average call is "buy". The mean target, $46.56, sits 28.0% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 800 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
10 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
ROIV is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-07-06, the strategy has returned 1524.8% (321.7% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $46.56, 28.0% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $39.95, so shares trade 8.9% below that estimate. On earnings multiple, it sits in the 2nd percentile of its own five-year valuation range (cheaper than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Quote as of Oct 1, 2026 11:50 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 800 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$36.38 is the latest print for ROIV, a move of -0.52% against yesterday's close of $36.57. Today's low and high so far: $36.15 and $36.79.
Equity value comes to $26.28B at the current price. By that measure it is number 476 of the 800 names in our coverage.
The year's floor is $15.25 and the ceiling $42.50. Shares are 14.4% away from that ceiling.
Our data shows no dividend paid by Roivant Sciences over the trailing twelve months.
Of 10 analysts, 90% say buy, 10% hold and 0% sell. Price targets average $46.56, with the most cautious at $40.00 and the most optimistic at $55.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on ROIV.